Eli Lilly CEO Dave Ricks Talks Fighting Obesi...

JPMorgan Chase Chair and CEO Jamie Dimon says there is "too much" exuberance in the markets. Speaking with Bloomberg's Francine Lacqua from the JP Morgan Global Markets Conference in Paris, France, Dimon also commented on the use of artificial intelligence, cybersecurity, and ban ...  Show more

Ed Yardeni, Yardeni Research, joined Bloomberg's Tom Keene and Paul Sweeney to discuss “extraordinary” first-quarter earnings results as he boosts his year-end target for the S&P 500 to 8,250. He discusses the role of the consumer in driving economic resilience and says he’s “not ...  Show more

Bloomberg BNA's Eleanor Tyler joins Tom Keene and Mike McKee to discuss pharmaceutical mergeres, tax inversions, drug pricing, and the renewed efforts by the Federal Trade Commission to regulate an increasingly complicated industry. Learn more about your ad-choices at https://www ...  Show more

Bloomberg Opinion Pharma Columnist Lisa Jarvis and Bloomberg News Health Reporter Madison Muller discuss a how a clinical trial in obesity drugs is punctuating a string of positive developments that could make the treatments more widely accessible. Kate Hao, Founder and CEO of Ha ...  Show more

When fast-food chain Raising Cane’s tapped the US capital market this month, it revealed a $7.6 billion fortune held by CEO Todd Graves. Strong demand for the chicken-finger maker’s bonds highlights growing investor appetite for risky debt as the US economy appears headed for a s ...  Show more

The Dow was down 942 points at its session lows in a September-style selloff to start the week and Jim Cramer is helping investors navigate the day’s volatility. Then, as pharmaceutical companies focus on COVID-19, Eli Lilly CEO Dave Ricks checks in to discuss the company's pr ...